190 related articles for article (PubMed ID: 29938870)
1. Survival analysis of multiple peptide vaccination for the selection of correlated peptides in urological cancers.
Noguchi M; Koga N; Moriya F; Suekane S; Yutani S; Yamada A; Shichijo S; Kakuma T; Itoh K
Cancer Sci; 2018 Sep; 109(9):2660-2669. PubMed ID: 29938870
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time.
Noguchi M; Moriya F; Suekane S; Ohnishi R; Matsueda S; Sasada T; Yamada A; Itoh K
BMC Cancer; 2013 Dec; 13():613. PubMed ID: 24373380
[TBL] [Abstract][Full Text] [Related]
3. Personalized peptide vaccines and their relation to other therapies in urological cancer.
Kimura T; Egawa S; Uemura H
Nat Rev Urol; 2017 Aug; 14(8):501-510. PubMed ID: 28561807
[TBL] [Abstract][Full Text] [Related]
4. A Phase 2 Randomized Controlled Trial of Personalized Peptide Vaccine Immunotherapy with Low-dose Dexamethasone Versus Dexamethasone Alone in Chemotherapy-naive Castration-resistant Prostate Cancer.
Yoshimura K; Minami T; Nozawa M; Kimura T; Egawa S; Fujimoto H; Yamada A; Itoh K; Uemura H
Eur Urol; 2016 Jul; 70(1):35-41. PubMed ID: 26782346
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin.
Matsumoto K; Noguchi M; Satoh T; Tabata K; Fujita T; Iwamura M; Yamada A; Komatsu N; Baba S; Itoh K
BJU Int; 2011 Sep; 108(6):831-8. PubMed ID: 21166757
[TBL] [Abstract][Full Text] [Related]
6. Immunological evaluation of personalized peptide vaccination for patients with histologically unfavorable carcinoma of unknown primary site.
Sakamoto S; Yutani S; Shichijo S; Morita M; Yamada A; Itoh K; Noguchi M
Cancer Immunol Immunother; 2016 Oct; 65(10):1223-31. PubMed ID: 27549314
[TBL] [Abstract][Full Text] [Related]
7. A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer.
Noguchi M; Moriya F; Koga N; Matsueda S; Sasada T; Yamada A; Kakuma T; Itoh K
Cancer Immunol Immunother; 2016 Feb; 65(2):151-60. PubMed ID: 26728480
[TBL] [Abstract][Full Text] [Related]
8. A randomized phase III trial of personalized peptide vaccination for castration‑resistant prostate cancer progressing after docetaxel.
Noguchi M; Fujimoto K; Arai G; Uemura H; Hashine K; Matsumoto H; Fukasawa S; Kohjimoto Y; Nakatsu H; Takenaka A; Fujisawa M; Uemura H; Naito S; Egawa S; Fujimoto H; Hinotsu S; Itoh K
Oncol Rep; 2021 Jan; 45(1):159-168. PubMed ID: 33200227
[TBL] [Abstract][Full Text] [Related]
9. [Peptide vaccination for castration-resistant prostate cancer].
Koga N; Noguchi M
Nihon Rinsho; 2014 Dec; 72(12):2147-51. PubMed ID: 25518349
[TBL] [Abstract][Full Text] [Related]
10. Potential survival benefit of anti-apoptosis protein: survivin-derived peptide vaccine with and without interferon alpha therapy for patients with advanced or recurrent urothelial cancer--results from phase I clinical trials.
Tanaka T; Kitamura H; Inoue R; Nishida S; Takahashi-Takaya A; Kawami S; Torigoe T; Hirohashi Y; Tsukamoto T; Sato N; Masumori N
Clin Dev Immunol; 2013; 2013():262967. PubMed ID: 24363758
[TBL] [Abstract][Full Text] [Related]
11. Immunological evaluation of personalized peptide vaccination monotherapy in patients with castration-resistant prostate cancer.
Uemura H; Fujimoto K; Mine T; Uejima S; de Velasco MA; Hirao Y; Komatsu N; Yamada A; Itoh K
Cancer Sci; 2010 Mar; 101(3):601-8. PubMed ID: 20128819
[TBL] [Abstract][Full Text] [Related]
12. Prospect and progress of personalized peptide vaccinations for advanced cancers.
Sakamoto S; Noguchi M; Yamada A; Itoh K; Sasada T
Expert Opin Biol Ther; 2016; 16(5):689-98. PubMed ID: 26938083
[TBL] [Abstract][Full Text] [Related]
13. Personalized peptide vaccination as second-line treatment for metastatic upper tract urothelial carcinoma.
Suekane S; Ueda K; Nishihara K; Sasada T; Yamashita T; Koga N; Yutani S; Shichijo S; Itoh K; Igawa T; Noguchi M
Cancer Sci; 2017 Dec; 108(12):2430-2437. PubMed ID: 28940789
[TBL] [Abstract][Full Text] [Related]
14. Immunological efficacy of herbal medicines in prostate cancer patients treated by personalized peptide vaccine.
Koga N; Moriya F; Waki K; Yamada A; Itoh K; Noguchi M
Cancer Sci; 2017 Dec; 108(12):2326-2332. PubMed ID: 28898532
[TBL] [Abstract][Full Text] [Related]
15. Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients.
Yutani S; Ueshima K; Abe K; Ishiguro A; Eguchi J; Matsueda S; Komatsu N; Shichijo S; Yamada A; Itoh K; Sasada T; Kudo M; Noguchi M
J Immunol Res; 2015; 2015():473909. PubMed ID: 26539554
[TBL] [Abstract][Full Text] [Related]
16. Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide.
Voutsas IF; Anastasopoulou EA; Tzonis P; Papamichail M; Perez SA; Baxevanis CN
J Immunother Cancer; 2016; 4():75. PubMed ID: 27891225
[TBL] [Abstract][Full Text] [Related]
17. Case Report: Targeting of individual somatic tumor mutations by multipeptide vaccination tailored for HLA class I and II presentation induces strong CD4 and CD8 T-cell responses in a patient with metastatic castration sensitive prostate cancer.
Zelba H; Rabsteyn A; Bartsch O; Kyzirakos C; Kayser S; Seibold M; Harter J; Latzer P; Hadaschik D; Battke F; Golf A; Rettig MB; Biskup S
Front Immunol; 2023; 14():1271449. PubMed ID: 37920460
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of personalized peptide vaccination for castration-resistant prostate cancer patients who failed in docetaxel-based chemotherapy.
Noguchi M; Moriya F; Suekane S; Matsuoka K; Arai G; Matsueda S; Sasada T; Yamada A; Itoh K
Prostate; 2012 Jun; 72(8):834-45. PubMed ID: 21932426
[TBL] [Abstract][Full Text] [Related]
19. An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy.
Noguchi M; Matsumoto K; Uemura H; Arai G; Eto M; Naito S; Ohyama C; Nasu Y; Tanaka M; Moriya F; Suekane S; Matsueda S; Komatsu N; Sasada T; Yamada A; Kakuma T; Itoh K
Clin Cancer Res; 2016 Jan; 22(1):54-60. PubMed ID: 26581246
[TBL] [Abstract][Full Text] [Related]
20. Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients.
Kawano K; Tsuda N; Matsueda S; Sasada T; Watanabe N; Ushijima K; Yamaguchi T; Yokomine M; Itoh K; Yamada A; Kamura T
Immunopharmacol Immunotoxicol; 2014 Jun; 36(3):224-36. PubMed ID: 24773550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
